Cargando…
Nanomicellar Formulations Loaded with Histamine and Paclitaxel as a New Strategy to Improve Chemotherapy for Breast Cancer
Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype. Currently, paclitaxel (PTX) represents the first-line therapy for TNBC; however it presents a hydrophobic behavior and produces severe adverse effects. The aim of this work is to improve the therapeutic index of PTX t...
Autores principales: | Nicoud, Melisa B., Ospital, Ignacio A., Táquez Delgado, Mónica A., Riedel, Jennifer, Fuentes, Pedro, Bernabeu, Ezequiel, Rubinstein, Mara R., Lauretta, Paolo, Martínez Vivot, Rocío, Aguilar, María de los Ángeles, Salgueiro, María J., Speisky, Daniela, Moretton, Marcela A., Chiappetta, Diego A., Medina, Vanina A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959774/ https://www.ncbi.nlm.nih.gov/pubmed/36834958 http://dx.doi.org/10.3390/ijms24043546 |
Ejemplares similares
-
Histamine in cancer immunology and immunotherapy. Current status and new perspectives
por: Sarasola, María de la Paz, et al.
Publicado: (2021) -
Immunomodulatory role of histamine H4 receptor in breast cancer
por: Sterle, Helena A., et al.
Publicado: (2018) -
Study of the antitumour effects and the modulation of immune response by histamine in breast cancer
por: Nicoud, Melisa B., et al.
Publicado: (2019) -
Pathophysiological Role of Histamine H4 Receptor in Cancer: Therapeutic Implications
por: Nicoud, Melisa B., et al.
Publicado: (2019) -
(99m)Tc-Radiolabeled TPGS Nanomicelles Outperform (99m)Tc-Sestamibi as Breast Cancer Imaging Agent
por: Tesan, Fiorella C., et al.
Publicado: (2019)